Pharmacy automation company ARxIUM declared on Tuesday that its RIVA systems have accurately and safely prepared more than 10 million IV doses across all global installations.
This represents the production of patient-specific and batch IV doses of syringes and bags in acute care hospitals, centralised pharmacies and cancer centres. The GMP RIVA system contains several new features that are designed to meet Current Good Manufacturing Practice regulations for environmental monitoring, disclosed the company.
According to the company, RIVA, the most advanced, fully automated IV compounding system available, increases patient safety by reducing errors and contamination and minimising pharmacy technicians' exposure to hazardous preparations. It reduces the cost-per-dose of medications, need for outsourcing and pharmacy waste. This has resulted in many installations achieving more than a 100% return on investment in less than three years due to substantial costs savings and operational efficiencies such as high capacity inventory, long batch runs and the elimination of manual processes.
Earlier this year, three RIVA systems began compounding medications at two 503B hospitals in Florida. Combined, the GMP RIVA systems have already produced more than 110,000 doses, revealed the company.
At the 2019 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition in Las Vegas, the company will showcase the updated GMP RIVA f from 9 December-11 December 2019 in booth 2019.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories